Effect of Helpers Program On-line Training on Smoking Relapse and Social Networks
Launched by UNIVERSITY OF COLORADO, DENVER · Nov 29, 2022
Trial Information
Current as of January 14, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Despite major gains in smoking cessation treatment, over half of recently quit smokers will relapse within the first year. To date, relapse prevention interventions have focused on the newly abstinent smoker ("abstainer"), and not attempted to directly or indirectly influence the abstainer's personal network, e.g. by helping the abstainer influence others in their personal network to quit. Personal networks exert powerful effects on initiating and maintaining smoking behavior, and can facilitate maintaining abstinence or trigger relapse. A "help others" intervention that seeks to increase t...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years or older
- • Abstinent from smoking for between 14 and 60 days
- • Primary tobacco use is cigarettes
- • Has access to Internet via computer or mobile device
- • Self-described proficiency with English
- • Willing and able to send/receive weekly text messages using personal mobile phone plan
- • Will allow Quitline to share their client data with research team
- • Willing to complete online surveys at baseline, 3-, 6-, 9- and 12 months
- • Willing to self-collect dried blood spot and send back to research team
- • If assigned to Helpers Stay Quit condition, willing to complete training within 14 days
- • If selected, willing to participate in qualitative interview
- • Willing to forego any other training for tobacco cessation intervention/support (i.e., to become a cessation counselor/facilitator or support person, e.g., 'quit buddy') for the duration of their study enrollment
- Exclusion Criteria:
- • Any prior exposure to Helpers training or other cessation training in the previous 2 years
Trial Officials
Myra Muramoto, MD, MPH
Principal Investigator
University of Colorado School of Medicine
About University Of Colorado, Denver
The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aurora, Colorado, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials